ARK Genomic Revolution ETF vs ZIM Integrated Shipping Services Ltd — how do they compare? ARK Genomic Revolution ETF trades at $44.62, while ZIM Integrated Shipping Services Ltd trades at $25.24 (market cap $2.96B). The key difference: ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, ZIM Integrated Shipping Services Ltd nearer its low. Which is the better fit depends on your goals.
| ARKG | ZIM | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $44.55 | $29.27 |
52-Week Low | $24.02 | $12.44 |
Market Cap | — | $2.96B |
Enterprise Value | — | $6.81B |
Dividend Yield | — | 20.16% |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.69 with a 0.86% daily gain, showing bullish momentum with strong moving average signals but overbought oscillators. The ETF focuses on genomic revolution companies with 59% concentration in top 10 holdings and long-term EPS growth of 10.7%. Recent news highlights biotech sector strength and ARKG's recovery from July correction.
Outlook remains positive given biotech sector tailwinds including FDA friendliness and AI-driven drug discovery, though high RSI readings suggest near-term caution. Key risks include sector volatility and concentrated portfolio exposure.
ZIM trades at $25.27, up 0.24% on the day, amid a bearish technical signal and mixed earnings history. The company reported a net income of $479.20 million in 2025, but profitability is expected to decline sharply in 2026. Recent news highlights uncertainty around a potential merger with Hapag-Lloyd and pressure from lower freight rates.
The outlook is cautious, with analysts evenly split between hold and sell ratings and a consensus price target of $16.75, well below the current price. Key risks include regulatory hurdles for the merger, volatile shipping rates, and declining earnings. Upside depends on successful deal execution or improved operational performance.
Trailing returns across standard periods
Latest headlines on both assets
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →